The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1032
July 31, 1998
View Complete Issue         Table of Contents 2019 
Recombinant Interleukin-11 for Chemotherapy-Induced Thrombocytopenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Recombinant Interleukin-11 for Chemotherapy-Induced Thrombocytopenia
July 31, 1998 (Issue: 1032)
The US Food and Drug Administration (FDA) has approved use of recombinant human interleukin 11 (rhIL-11; oprelvekin; Neumega - Genetics Institute) to increase platelet counts and decrease the need for platelet transfusions in patients with severe ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Recombinant Interleukin-11 for Chemotherapy-Induced Thrombocytopenia
Article code: 1032b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.